Tuesday, May 15, 2018

Benralizumab for treating patients with severe eosinophilic asthma

Benralizumab injection for subcutaneous use has been approved by the US FDA in November 2017 for treating patients with severe eosinophilic asthma.
Benralizumab is a type of monoclonal antibody which is prescribed as an add-on maintenance treatment for treating severe eosinophilic asthma in patients 12 years of age and older.
Benralizumab comes as an injection which is available as a single dose prefilled syringe to be administered subcutaneously or just under the skin.

Monday, May 14, 2018

Substance-induced psychosis may lead to development schizophrenia, bipolar disorder

A robust association exists between substance-induced psychosis and the development of severe mental illness, a recent study has shown, adding that a long follow-up period is warranted to identify most of these cases. 

Risk of suicide following nonfatal attempt high in adolescents, young adults

Adolescents and young adults appear to have a significantly increased risk of suicide following nonfatal self-harm, a study reports. Among this high-risk population, those who have used violent self-harm methods, particular firearms, are at especially greater risk. 

Children born to consanguineous parents more likely to have poor mental health

Children of consanguineous parents appear to be at a higher risk of common mood disorders and psychosis, a recent Ireland study has shown.

Cognitive impairment associated with frailty and increased mortality

Those who are cognitively impaired are more likely to develop frailty after 4 years, leading to impairment in motor activities, delayed recall, poorer quality of life and increased mortality rate, a study in Hong Kong recently showed. 

Conversion disorder associated with stressful life events

A study recently showed that conversion disorder, also known as the functional neurological disorder, is associated with stressful life events and maltreatment.

Benralizumab for treating patients with severe eosinophilic asthma

Benralizumab injection for subcutaneous use has been approved by the US FDA in November 2017 for treating patients with severe eosinophilic ...